NASDAQ: BEAM | Healthcare / Biotechnology / USA |
21.54 | -0.8500 | -3.80% | Vol 957.36K | 1Y Perf -56.61% |
Oct 4th, 2023 16:00 DELAYED |
BID | 21.00 | ASK | 22.36 | ||
Open | 22.47 | Previous Close | 22.39 | ||
Pre-Market | - | After-Market | 21.55 | ||
- - | 0.01 0.05% |
Target Price | 77.67 | Analyst Rating | Moderate Buy 1.57 | |
Potential % | 260.59 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★+ 43.94 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 1.56 | Earnings Rating | — | |
Market Cap | 1.71B | Earnings Date | 6th Nov 2023 | |
Alpha | 0.01 | Standard Deviation | 0.26 | |
Beta | 1.57 |
Today's Price Range 21.0222.60 | 52W Range 21.0254.30 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -7.71% | ||
1 Month | -4.56% | ||
3 Months | -29.88% | ||
6 Months | -24.28% | ||
1 Year | -56.61% | ||
3 Years | 0.67% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -88.34 | |||
ROE last 12 Months | -40.23 | |||
ROA (5Y Avg) | -12.25 | |||
ROA last 12 Months | -25.17 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -33.51 | |||
Return on invested Capital Q | -11.76 | |||
Return on invested Capital Y | -56.38 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-9.00 | ||||
3.98 | ||||
66.67 | ||||
29.90 | ||||
55.80 | ||||
1.35 | ||||
3.98 | ||||
10.14 | ||||
1.93B | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
4.60 | ||||
4.60 | ||||
0.19 | ||||
0.24 | ||||
-1 066.00 | ||||
Leverage Ratio | 1.80 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-340.40 | ||||
-326.40 | ||||
- | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
40.88M | ||||
0.58 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -1.38 | -1.08 | 21.74 |
Q01 2023 | -1.36 | -1.33 | 2.21 |
Q04 2022 | -1.32 | -0.54 | 59.09 |
Q03 2022 | -1.30 | -1.56 | -20.00 |
Q02 2022 | -1.08 | -1.02 | 5.56 |
Q01 2022 | -1.10 | -1.01 | 8.18 |
Q04 2021 | -1.02 | -0.85 | 16.67 |
Q03 2021 | -0.78 | -0.42 | 46.15 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | 6th Nov 2023 |
Estimated EPS Next Report | -1.32 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 957.36K |
Shares Outstanding | 79.20K |
Shares Float | 75.71M |
Trades Count | 14.53K |
Dollar Volume | 20.50M |
Avg. Volume | 896.39K |
Avg. Weekly Volume | 916.96K |
Avg. Monthly Volume | 926.18K |
Avg. Quarterly Volume | 846.02K |
Beam Therapeutics Inc. (NASDAQ: BEAM) stock closed at 22.39 per share at the end of the most recent trading day (a 4.14% change compared to the prior day closing price) with a volume of 975.14K shares and market capitalization of 1.71B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 166 people. Beam Therapeutics Inc. CEO is John Evans.
The one-year performance of Beam Therapeutics Inc. stock is -56.61%, while year-to-date (YTD) performance is -42.75%. BEAM stock has a five-year performance of %. Its 52-week range is between 21.02 and 54.3, which gives BEAM stock a 52-week price range ratio of 1.56%
Beam Therapeutics Inc. currently has a PE ratio of -9.00, a price-to-book (PB) ratio of 3.98, a price-to-sale (PS) ratio of 66.67, a price to cashflow ratio of 29.90, a PEG ratio of -, a ROA of -25.17%, a ROC of -33.51% and a ROE of -40.23%. The company’s profit margin is -%, its EBITDA margin is -326.40%, and its revenue ttm is $40.88 Million , which makes it $0.58 revenue per share.
Of the last four earnings reports from Beam Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.32 for the next earnings report. Beam Therapeutics Inc.’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for Beam Therapeutics Inc. is Moderate Buy (1.57), with a target price of $77.67, which is +260.59% compared to the current price. The earnings rating for Beam Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Beam Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Beam Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.12, ATR14 : 1.20, CCI20 : -197.38, Chaikin Money Flow : -0.02, MACD : -0.66, Money Flow Index : 24.71, ROC : -10.62, RSI : 38.68, STOCH (14,3) : 27.96, STOCH RSI : 0.47, UO : 46.14, Williams %R : -72.04), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Beam Therapeutics Inc. in the last 12-months were: Amy Simon (Sold 16 099 shares of value $480 843 ), Burrell Terry-Ann (Sold 0 shares of value $-1 332 104 ), Burrell Terry-Ann (Sold 109 325 shares of value $4 858 728 ), Christine Bellon (Sold 2 092 shares of value $61 996 ), Ciaramella Giuseppe (Option Excercise at a value of $54 371), Ciaramella Giuseppe (Sold 57 401 shares of value $2 121 648 ), Evans John (Sold 0 shares of value $-99 997 ), Evans John (Sold 11 654 shares of value $345 311 ), Giuseppe Ciaramella (Option Excercise at a value of $103 084), Giuseppe Ciaramella (Sold 108 416 shares of value $4 299 882 ), John Evans (Sold 11 654 shares of value $345 334 ), Simon Amy (Sold 391 shares of value $11 918 ), Terry-Ann Burrell (Option Excercise at a value of $1 332 104), Terry-Ann Burrell (Sold 109 325 shares of value $4 858 817 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises of Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
CEO: John Evans
Telephone: +1 857 327-8775
Address: 26 Landsdowne Street, Cambridge 02139, MA, US
Number of employees: 166
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.